Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

Merz Pharmaceuticals GmbH30 enrolled

Overview

Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Conducted in Europe

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

Botulinum neurotoxin type A, free of complexing proteinsDRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy females, 18 to 65 years

Locations (1)

Merz Pharmaceuticals GmbH

Frankfurt am Main, Germany

Outcomes

Primary Outcomes

Measurement of area

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.